Hawrylowicz C M, O'Garra A
Department of Asthma, Allergy & Respiratory Science, Guy's Hospital, King's College London, London SE1 9RT, UK.
Nat Rev Immunol. 2005 Apr;5(4):271-83. doi: 10.1038/nri1589.
Allergic diseases are caused by aberrant T-helper-2 immune responses in susceptible individuals. Both naturally occurring CD4(+)CD25(+) regulatory T cells and inducible populations of antigen-specific interleukin-10-secreting regulatory T cells inhibit these inappropriate immune responses in experimental models. This article discusses the evidence that regulatory T-cell function might be impaired in allergic and asthmatic disease and that certain therapeutic regimens might function, at least in part, to promote regulatory T-cell generation. Current research strategies seek to exploit these observations to improve the generation of allergen-specific regulatory T-cell populations with the potential to provide the safe and long-term alleviation of disease symptoms.
过敏性疾病是由易感个体中异常的辅助性T细胞2型免疫反应引起的。天然存在的CD4(+)CD25(+)调节性T细胞和可诱导产生的分泌白细胞介素-10的抗原特异性调节性T细胞群体在实验模型中均可抑制这些不适当的免疫反应。本文讨论了如下证据:在过敏性和哮喘性疾病中调节性T细胞功能可能受损,且某些治疗方案可能至少部分地通过促进调节性T细胞的生成发挥作用。当前的研究策略旨在利用这些观察结果,以改善具有潜在能力提供安全且长期缓解疾病症状的过敏原特异性调节性T细胞群体的生成。